Cargando…

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors

BACKGROUND & AIM: To compare the efficacy of pegylated-interferon (Peg-IFN) α-2a or α-2b and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus boceprevir or telaprevir) in patients with HCV-1 chronic hepatitis naïve for anti-HCV therapy or relapsers to dual therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coppola, Nicola, Pisaturo, Mariantonietta, Sagnelli, Caterina, Sagnelli, Evangelista, Angelillo, Italo F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984165/ https://www.ncbi.nlm.nih.gov/pubmed/24728219 http://dx.doi.org/10.1371/journal.pone.0094542

Ejemplares similares

Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2012)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
por: Sagnelli, Evangelista, et al.
Publicado: (2012)

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
por: Sagnelli, Caterina, et al.
Publicado: (2019)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Epidemiology and management of hepatitis C virus infections in immigrant populations
por: Coppola, Nicola, et al.
Publicado: (2019)

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2016)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features
por: Coppola, Nicola, et al.
Publicado: (2017)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression
por: Coppola, Nicola, et al.
Publicado: (2013)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies
por: Wedemeyer, Heiner, et al.
Publicado: (2016)

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy
por: Stroffolini, Tommaso, et al.
Publicado: (2018)

Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
por: Christensen, Stefan, et al.
Publicado: (2014)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort
por: Kjellin, Midori, et al.
Publicado: (2018)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy
por: Alessio, Loredana, et al.
Publicado: (2018)

Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma
por: Sagnelli, Evangelista, et al.
Publicado: (2018)

SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2017)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4dlu11j20crltuvbfb19msgsge